



Electric Tumor Treatment Fields (TTF) Device

Last Revision/Review Date: May 15, 2019

P&P # C.11.23

Policy

The Medical Management Department reviews referral requests for authorization of Electric Tumor Treatment Fields (TTF) devices for treatment of glioblastoma multiforme (GBM).

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee's specific plan document must be referenced. The terms of an enrollee's plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee's specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

Procedure

I. Documentation Required:

In order to facilitate the authorization process, referral requests **MUST** include the following:

1. Diagnosis of supratentorial glioblastoma multiforme (GBM).
2. History of prior treatment for GBM
3. Physician assessment, plan of care and order for the requested electric tumor treatment field device.

II. Criteria for Medical Necessity:

A. Initial Rental of an Electric Tumor Treatment Field (TTF) Device

A three (3) month rental of an FDA approved TTF device is considered medically necessary for adults ages 22 and older when **EITHER** of the following are met:

- a. As monotherapy for recurrent histologically confirmed GBM when **BOTH** of the following are met:
 - i. The patient has a Karnofsky Performance Status score of 60 or higher;
AND
 - ii. The patient or caregiver is willing and able to apply and maintain the device an average of at least 18 hours per day; **OR**
- b. As adjunctive therapy with concomitant temozolomide for newly diagnosed, histologically confirmed GBM after tumor debulking, completion of chemotherapy and radiation therapy when **BOTH** of the following are met:
 - i. The patient has a Karnofsky Performance Status score of 60 or higher;
AND
 - ii. The patient or caregiver is willing and able to apply and maintain the device an average of at least 18 hours per day.

B. Continuation of Rental of an Electric Tumor Treatment Field (TTF) Device

Continuation of rental of the TTF device will be authorized monthly, contingent upon a compliance report that documents an average of at least 18 hrs of use per day and **BOTH** of the following are met:

- a. The patient has been evaluated by their oncologist within the last 3 months and has a Karnofsky Performance Status score of 60 or higher; **AND**
- b. Patient has no evidence of disease progression on follow-up imaging performed within the last 3 months.

III. Indications Considered Experimental/Investigational or Not Medically Necessary (Not an all-inclusive list):

1. TTF devices used for treatment of any malignant tumors other than those identified in this policy.
2. Continuation of rental for patients without updated imaging completed as least every 3 months.
3. Treatment with Electronic Tumor Treatment Fields device (Optune®) for patients that have a history of disease progression while using TTF treatment.
4. Concomitant therapy with any other chemotherapeutic or immunotherapy agent other than temozolomide for adjuvant therapy.

CPT/HCPCS CODES:

A4555	Electrode/Transducer for use with electrical stimulation device used for cancer treatment, replacement only.
E0766	Electrical stimulation device, used for cancer treatment, includes all accessories, any type.

REFERENCES:

Hayes, Inc. Medical Technology Directory. Novocure (Tumor Treating Fields). Published March 3, 2016. Annual review January 25, 2019. Accessed March 20, 2019.

Mun EJ, Babiker HM, Weinberg ED, Kirson ED, Von Hoff DD. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res. 2018;24(2):266-27
NCCN Clinical Practice Guidelines in Oncology®. © 2018 National Comprehensive Cancer Network, Inc. <http://www.nccn.org/index.asp>.

- Central Nervous System Cancers (V.1.2019). March 5, 2019. Accessed March 20, 2019.
- Melanoma (V.2.2019). March 12, 2019. Accessed March 20, 2019.
- Non-Small Cell Lung Cancer (V.3.2019). January 18, 2019. Accessed March 20, 2019.

Stupp R, Tailibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. A randomized clinical trial. JAMA. 2015; 314:2535-2543.

U.S. Food and Drug Administration (FDA) Premarket Notification Database. Tumor Treatment Fields. NovoTTF-10A System. Summary of Safety and Effectiveness Data (SSED). No. P100034. Rockville, MD: FDA. April 8, 2011b. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. Accessed March 20, 2019.

U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) Database. Premarket Notification Database. Tumor Treatment Fields. Optune™. Summary of Safety and Effectiveness Data (SSED). No. P100034/S013. Rockville, MD: FDA. October 5, 2015. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034s013b.pdf . Accessed March 20, 2019